Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Burning Rock Biotech (BNR) EBT Margin: 2019-2025

Historic EBT Margin for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to -7.70%.

  • Burning Rock Biotech's EBT Margin rose 8543.00% to -7.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.79%, marking a year-over-year increase of 11272.00%. This contributed to the annual value of -66.06% for FY2024, which is 5513.00% up from last year.
  • Latest data reveals that Burning Rock Biotech reported EBT Margin of -7.70% as of Q3 2025, which was up 3.02% from -7.94% recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's EBT Margin registered a high of -7.70% during Q3 2025, and its lowest value of -200.76% during Q2 2022.
  • Its 3-year average for EBT Margin is -75.19%, with a median of -89.42% in 2023.
  • As far as peak fluctuations go, Burning Rock Biotech's EBT Margin crashed by 9,235bps in 2021, and later soared by 11,133bps in 2023.
  • Burning Rock Biotech's EBT Margin (Quarterly) stood at -170.71% in 2021, then tumbled by 1,034bps to -181.06% in 2022, then skyrocketed by 6,410bps to -116.96% in 2023, then soared by 5,774bps to -59.22% in 2024, then skyrocketed by 8,543bps to -7.70% in 2025.
  • Its EBT Margin was -7.70% in Q3 2025, compared to -7.94% in Q2 2025 and -9.98% in Q1 2025.